Caspofungin Dose Escalation for Invasive Candidiasis Due to Resistant Candida albicans
Open Access
- 1 July 2011
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 55 (7) , 3254-3260
Abstract
Previous in vivo studies have reported caspofungin dose escalation to be effective against Candida glabrata with reduced susceptibility. We hypothesized that higher doses of caspofungin would be effective against invasive candidiasis caused by the more virulent species Candida albicans , including isolates resistant to this echinocandin. Immunocompetent mice were inoculated with one of three C. albicans isolates, including one susceptible and two resistant isolates with different FKS1 hot spot 1 point mutations. Mice received daily caspofungin treatment for 7 days and were then followed off therapy for 2 weeks to assess survival. Kidney tissue and blood were collected, and fungal burden and serum (1→3)-β- d -glucan were measured. Significant differences in virulence were observed among the three C. albicans isolates, which translated into differences in responses to caspofungin. The most virulent of the resistant isolates studied (isolate 43001; Fks1p F641S) did not respond to caspofungin doses of up to 10 mg/kg of body weight, as there were no differences in survival (survival range, 0 to 12% with treatment), tissue burden, or (1→3)-β- d -glucan concentration compared to those for untreated controls. Higher doses of caspofungin did improve survival against the second resistant isolate (53264; Fks1p S645P) that demonstrated reduced virulence (5 and 10 mg/kg; 80% survival). In contrast, caspofungin doses as low as 1 mg/kg improved survival (85 to 95%) and reduced tissue burden and (1→3)-β- d -glucan concentration against the susceptible isolate (ATCC 90028). These data suggest that caspofungin dose escalation for invasive candidiasis may not be consistently effective against resistant C. albicans isolates, and this may be associated with the virulence of the strain.Keywords
This publication has 36 references indexed in Scilit:
- In Vivo Comparison of the Pharmacodynamic Targets for Echinocandin Drugs against Candida SpeciesAntimicrobial Agents and Chemotherapy, 2010
- Amphotericin B and Caspofungin Resistance in Candida glabrata Isolates Recovered from a Critically Ill PatientClinical Infectious Diseases, 2006
- Pharmacodynamics of Caspofungin in a Murine Model of Systemic Candidiasis: Importance of Persistence of Caspofungin in Tissues to Understanding Drug ActivityAntimicrobial Agents and Chemotherapy, 2005
- Specific Substitutions in the Echinocandin Target Fks1p Account for Reduced Susceptibility of Rare Laboratory and Clinical Candida sp. IsolatesAntimicrobial Agents and Chemotherapy, 2005
- Safety, Tolerability, and Pharmacokinetics of Micafungin (FK463) in Febrile Neutropenic Pediatric PatientsAntimicrobial Agents and Chemotherapy, 2005
- Pharmacokinetic and Maximum Tolerated Dose Study of Micafungin in Combination with Fluconazole versus Fluconazole Alone for Prophylaxis of Fungal Infections in Adult Patients Undergoing a Bone Marrow or Peripheral Stem Cell TransplantAntimicrobial Agents and Chemotherapy, 2005
- Pharmacodynamics of Caspofungin in a Murine Model of Invasive Pulmonary Aspergillosis: Evidence of Concentration‐Dependent ActivityThe Journal of Infectious Diseases, 2004
- The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacyExpert Opinion on Investigational Drugs, 2003
- The Antifungal Echinocandin Caspofungin Acetate Kills Growing Cells of Aspergillus fumigatus In VitroAntimicrobial Agents and Chemotherapy, 2002
- Effects of cilofungin (LY121019) on carbohydrate and sterol composition ofCandida albicansEuropean Journal of Clinical Microbiology & Infectious Diseases, 1989